<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346253</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-32058</org_study_id>
    <secondary_id>NCI-2015-00089</secondary_id>
    <secondary_id>PROS0065</secondary_id>
    <nct_id>NCT02346253</nct_id>
  </id_info>
  <brief_title>High-Dose Brachytherapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and how well high-dose brachytherapy works in
      treating patients with prostate cancer that has not spread to other parts of the body.
      Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles,
      seeds, wires, or catheters is placed directly into or near a tumor and may be a better
      treatment in patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the rate of acute (within six months of high-dose rate [HDR] completion) grade
      &gt;= 2 genitourinary (GU) toxicity following high-dose-rate (HDR) brachytherapy (BT) as
      monotherapy for newly diagnosed prostate cancer using the National Cancer Institute's Common
      Terminology Criteria for Adverse Events, version 3 (CTCAE v3.0).

      SECONDARY OBJECTIVES:

      I. To estimate the proportion of men with a prostate-specific antigen (PSA) nadir by one year
      (nPSA12) of &lt; 2 ng/mL.

      II. To estimate the rate of freedom from biochemical failure at 5 years (FFBF). III. To
      evaluate patient-reported quality of life via the 32-item Expanded Prostate Cancer Index
      Composite (EPIC).

      IV. To assess the cost-effectiveness of HDR BT as monotherapy for prostate cancer using the
      6-item European Quality of Life 5-Dimensions (EQ-5D).

      V. To explore pre-treatment clinical risk factors to optimize patient selection for HDR BT as
      monotherapy for prostate cancer.

      VI. To compare acute and late (&gt; 6 months after HDR completion) GU and gastrointestinal (GI)
      grade &gt;= 2 toxicity using CTCAE v3.0 and v4.0.

      VII. To explore dosimetric predictors of toxicity.

      OUTLINE:

      Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients may receive androgen
      deprivation therapy (ADT) comprising bicalutamide orally (PO) once daily (QD). Patients may
      also receive luteinizing hormone-releasing hormone (LHRH) agonist therapy comprising
      leuprolide acetate intramuscularly (IM) or subcutaneously (SC), goserelin acetate SC,
      triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving
      ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.

      After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months, and
      then yearly for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with acute grade 2 or greater acute GU toxicity, scored according to CTCAE v3.0</measure>
    <time_frame>Within 6 months of HDR completion</time_frame>
    <description>Will be calculated with a 90% confidence interval. Treatment plans will be reviewed, and doses to normal structures will be calculated and tabulated to determine possible relationships with toxicity outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of men with a nPSA12 of &lt; 2 ng/mL</measure>
    <time_frame>Up to 1 year after completion of HDR</time_frame>
    <description>nPSA12 is defined as the lowest PSA level achieved during the first year after completing HDR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFBF (Biochemical failure define according to PSA nadir+2ng/mL and 3 consecutive rises definition according to American Society of Radiation Oncology</measure>
    <time_frame>From the completion of all treatment to the time of BF, assessed at 5 years</time_frame>
    <description>Biochemical failure (BF) will be defined according the PSA nadir + 2 ng/mL and three consecutive rises definition according to the American Society of Radiation Oncology consensus recommendation. Time to first BF will be analyzed with competing risk models with death as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by EPIC scores</measure>
    <time_frame>Baseline to up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of HDR BT as monotherapy for prostate cancer using as measured by EQ-5D scores</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured utility values for each patient on this study will be combined with overall survival to calculate the &quot;QALY&quot; quality-adjusted life years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment clinical risk factors to optimize patient selection for HDR BT as monotherapy for prostate cancer (association between each risk factor and the risk of having a first BF)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical risk factors will be tested in competing risk models to evaluate the association between each risk factor and the risk of having a first BF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with acute grade 2 or greater acute GU toxicity, scored according to CTCAE v4.0</measure>
    <time_frame>Within 6 months of HDR completion</time_frame>
    <description>Will be calculated with a 90% confidence interval. Treatment plans will be reviewed, and doses to normal structures will be calculated and tabulated to determine possible relationships with toxicity outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late GU toxicity, scored according to CTCAE v3.0 and v4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be calculated with a 90% confidence interval. Treatment plans will be reviewed, and doses to normal structures will be calculated and tabulated to determine possible relationships with toxicity outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GI toxicity scored according to CTCAE v3.0 and CTCAE v4.0</measure>
    <time_frame>Up to 6 months after completing HDR BT</time_frame>
    <description>Will be calculated with a 90% confidence interval. Treatment plans will be reviewed, and doses to normal structures will be calculated and tabulated to determine possible relationships with toxicity outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late GI toxicity, scored according to CTCAE v3.0 and CTCAE v4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be calculated with a 90% confidence interval. Treatment plans will be reviewed, and doses to normal structures will be calculated and tabulated to determine possible relationships with toxicity outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetric predictors of toxicity (Doses to pelvic structures will be calculated and reviewed to determine possible correlations with toxicity outcomes)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Doses to pelvic structures will be calculated and reviewed to determine possible correlations with toxicity outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Internal Radiation Therapy</intervention_name>
    <description>Undergo high-dose-rate brachytherapy</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>Brachytherapy</other_name>
    <other_name>Internal Radiation</other_name>
    <other_name>Internal Radiation Brachytherapy</other_name>
    <other_name>Radiation Brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>CDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given IM or SC</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>A-43818</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>ICI-118630</other_name>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>Pamorelin</other_name>
    <other_name>Trelstar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented pathologic confirmation of prostate adenocarcinoma

          -  Clinical T-classification T1-3

          -  PSA &lt; 150 ng/mL

          -  Gleason score 6-10

          -  Clinically negative lymph nodes as established by abdomino-pelvic CT. CT only for
             clinical classification of T3 (with contrast if renal function is acceptable; a
             non-contrast CT is permitted if the patient is not a candidate for contrast), magnetic
             resonance imaging (MRI), nodal sampling, or dissection. Patients with lymph nodes
             equivocal or questionable by imaging are eligible if those nodes are &lt;1 cm in short
             axis diameter. [56]

          -  No evidence of bone metastases (M0) on bone scan, only for PSA &gt;20 ng/mLor Gleason â‰¥8,
             (NaF PET/CT is an acceptable substitute). Equivocal bone scan findings are allowed if
             plain films and/or MRI are negative for definite metastases.

          -  American Urological Association Symptom Index (AUA SI) =&lt; 20

        Exclusion Criteria:

          -  Clinical T4 disease

          -  PSA &gt;= 150 ng/mL

          -  AUA SI &gt; 20

          -  History of radical prostatectomy, external beam radiotherapy (EBRT), or BT for
             prostate cancer

          -  Previous chemotherapy for any malignancy, if given within three years of registration

          -  History of rectal surgery

          -  History of rectal fistula

          -  History of inflammatory bowel disease

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last six months

               -  Transmural myocardial infarction within the last six months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Buyyounouski</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matt Morales</last_name>
    <phone>650-721-4072</phone>
    <email>mmoral@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Morales</last_name>
      <phone>650-721-4072</phone>
      <email>mmoral@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Mark K. Buyyounouski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

